Generics are a bitter pill for Pfizer
The world's biggest drugmaker says it will lay off 10,000 jobs — about 10% of its workforce — due to threats to its sales from generic drugs. Stephen Beard reports.
TEXT OF STORY
KAI RYSSDAL: The world’s biggest drug maker is trying to stay that way. And Pfizer’s playing the percentages to do it.
The company announced huge layoffs today. 10,000 jobs. That’s about 10 percent of its work force. All of it driven by one simple number: Pfizer could lose as much as 40 percent of its sales to generic competition by 2012.
Today’s announcement’s the second time in less than a year the company’s tightened its belt. From London, Marketplace’s Stephen Beard has more.
STEPHEN BEARD: Pfizer is shutting down plants at Brooklyn and Omaha. Research laboratories are going in Michigan and in Japan and France. By the end of next year, the company’s global work force of 100,000 will be 10 percent smaller.
The cuts are necessary, says the chief executive. Profits are under pressure. Like many big drug companies, Pfizer is suffering withdrawal symptoms. It’s lost the patent protection on some of its best-selling medicines, like the antidepressant Zoloft.
An industry-wide problem, says Stephen Schondelmeyer of the Universiity of Minnesota.
STEPHEN SCHONDELMEYER: Companies aren’t finding innovative new products to replace those products before they go off patent. In the past, they’ve been able to do that. And companies are finding it increasingly difficult to find novel new compounds that become blockbusters in the marketplace.
Some researchers have reached the conclusion that medical science may have already found most of the chemical entities we’re going to find. A big, perhaps incurable, headache for the drug companies.
In London, this is Stephen Beard for Marketplace.